NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Jorge Alatorre-Alexander et al.|Journal of Clinical Oncology|2021Cited by 818
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018David S. Ettinger, Miranda Hughes, Dara L. Aisner et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 471
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Christine M. Lovly, Jennifer G. Whisenant et al.|Journal of Thoracic Oncology|2019Cited by 163